SCHEMBL752580

SCHEMBL752580

CCC(CCS(=O)(=O)O)COCC(CC)CCS(=O)(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.38
CYP3A4 P08684 4/20 0.35
TSHR P16473 2/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33
MMP14 P50281 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 2/20 0.33
CA2 P00918 2/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA7 P43166 1/20 0.31
CA14 Q9ULX7 1/20 0.31
ENPEP Q07075 4/20 0.31
S1PR2 O95136 1/20 0.31
S1PR1 P21453 1/20 0.31
S1PR3 Q99500 1/20 0.31
PTGS1 P23219 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266829 0.84 PTGS1 (0.38) RECQLALDH1A1CA2ENPEPS1PR2
SCHEMBL29714065 0.78 CA2 (0.38) RECQLCYP3A4TSHRTDP1ALDH1A1
SCHEMBL26305899 0.78 ALDH1A1 (0.48) RECQLALDH1A1ENPEPS1PR2S1PR1
Sulfuric Acid SCHEMBL25300462 0.78 RECQL (0.55) RECQLCYP3A4TSHRATMTDP1
SCHEMBL26687322 0.77 ALDH1A1 (0.46) TDP1ALDH1A1ENPEPS1PR2S1PR1
Sulfuric Acid SCHEMBL30386330 0.76 RECQL (0.54) RECQLCYP3A4TSHRATMTDP1
Sulfuric Acid SCHEMBL28669372 0.76 RECQL (0.54) RECQLCYP3A4TSHRATMTDP1
SCHEMBL837847 0.76 CYP3A4 (0.53) RECQLCYP3A4TSHRATMTDP1
SCHEMBL12752250 0.76 CYP3A4 (0.53) RECQLCYP3A4TSHRATMTDP1
SCHEMBL12786130 0.75 ENPEP (0.34) ENPEPS1PR2S1PR1S1PR3PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3100728-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CYDEX PHARMACEUTICALS INC (US) 2019-11-20 EP disclosed
US-10111863-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same CYDEX PHARMACEUTICALS, INC. (US) 2018-10-30 US disclosed
US-20170007586-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2017-01-12 US disclosed
EP-3100728-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME Cydex Pharmaceuticals, Inc. (US) 2016-12-07 EP disclosed
US-9399067-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same CYDEX PHARMACEUTICALS, INC. (US) 2016-07-26 US disclosed
EP-2429291-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CYDEX PHARMACEUTICALS INC (US) 2016-07-06 EP disclosed
US-20150005341-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-01-01 US disclosed
US-8835407-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same CYDEX PHARMACEUTICALS, INC. (US) 2014-09-16 US disclosed
US-20130012534-A1 Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same CYDEX PHARMACEUTICALS, INC. 2013-01-10 US disclosed
US-8236782-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same CYDEX PHARMACEUTICALS, INC. (US) 2012-08-07 US disclosed
EP-2429291-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CyDex Pharmaceuticals, Inc. (US) 2012-03-21 EP disclosed
WO-2010132711-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME CYDEX PHARMACEUTICALS, INC. (US) 2010-11-18 WO disclosed
US-20100291056-A1 Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170007586-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME P2RY6, GP6, PFKP RECQL 708/4885CYP3A4 41/4885TSHR 4698/4885
US-20150005341-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME P2RY6, GP6, PFKP RECQL 708/4885CYP3A4 41/4885TSHR 4698/4885
US-20130012534-A1 Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same P2RY6, GP6, PFKP RECQL 708/4885CYP3A4 41/4885TSHR 4698/4885
US-10111863-B2 Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same P2RY6, GP6, PFKP RECQL 708/4885CYP3A4 41/4885TSHR 4698/4885
US-20100291056-A1 Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same P2RY6, GP6, PFKP RECQL 708/4885CYP3A4 41/4885TSHR 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.